Sign inJoin waitlistJoin the waitlist

JM

Jason Melear

Physician · Texas Oncology

Credentials: · · · ·

History

Texas Oncology
Present

Baylor University Medical Center
1999–2001
Baylor University Medical Center
1996–1999
Texas Tech University Health Sciences Center School of Medicine
1992–1996

Research

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Nature Medicine · 2023 · 266 citations
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
British Journal of Haematology · 2019 · 65 citations
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
Nature Communications · 2023 · 62 citations

HY
Habte Yimer
5 papers
MN
Mohit Narang
4 papers
JB
John Burke
3 papers
DS
Don Stevens
2 papers
Ed Faber
2 papers
JR
John Renshaw
2 papers
RR
Robert Rifkin
2 papers
TL
Thomas Lin
2 papers
WB
William Bensinger
2 papers
Aaron Mansfield
1 paper
Adam Worthalter
1 paper
AC
Aileen Cohen
1 paper

Clinical trials

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Site PI · Recruiting · Phase 2
Loxo Oncology, Inc.
2025–2028
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Site PI · Recruiting · Phase 3
GlaxoSmithKline
2024–2031
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Site PI · Recruiting · Phase 2
Allogene Therapeutics
2024–2032